BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 104 resultados LastUpdate Última actualización 30/09/2022 [13:03:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 5 nextPage   por página


IBUPROFEN FOR SYMPTOMATIC TREATMENT OF DIARRHEAS IN HIV PATIENTS

NºPublicación: US2022304961A1 29/09/2022

Solicitante:

NIBHANIPUDI KUMARA V [US]

Resumen de: US2022304961A1

A method of treating noninfectious diarrhea in an HIV positive subject includes administering a dose of ibuprofen to the HIV positive subject at regular intervals until stool consistency is improved, diarrhea is alleviated, or the number of bowel movements per day are decreased. The dose is 400 mg of ibuprofen administered every 6 hours. The method may additionally include diagnosing the subject with noninfectious diarrhea, determining the subject does not have certain comorbidities, and/or determining that the subject is not taking any non-steroidal anti-inflammatory drugs. The method may additionally include after administering the ibuprofen, administering a clear liquids diet to the subject, administering an electrolyte supplement to the subject, and/or monitoring the subject for any bleeding from the gastrointestinal tract until stool consistency is improved, until diarrhea is alleviated, or until the number of bowel movements per day are decreased.

traducir

SYSTEM AND METHOD FOR DIAGNOSING SMALL BOWEL CLEANLINESS

NºPublicación: US2022304617A1 29/09/2022

Solicitante:

INTROMEDIC CO LTD [KR]

CN_114080644_PA

Resumen de: US2022304617A1

The present invention relates to a system for diagnosing small bowel cleanliness. The system may comprise: a similarity analysis unit for analyzing to select a representative image of similar small bowel images from among a plurality of small bowel images; an image classification unit for, when a series of a plurality of small bowel images in which cleanliness is to be diagnosed are received in a state where the plurality of small bowel images have been learned, classifying small bowel cleanliness according to scores by predicting the small bowel cleanliness by applying the representative image to a learning result; and a cleanliness diagnosis unit for calculating final small bowel cleanliness for the series of the plurality of small bowel images on the basis of a score for small bowel cleanliness of the representative image and the number of small bowel images similar to the representative image.

traducir

Methods and treatment involving excess free LIGHT

NºPublicación: AU2021248833A1 22/09/2022

Solicitante:

AVALO THERAPEUTICS INC

TW_202204405_A

Resumen de: AU2021248833A1

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

traducir

METHODS FOR REDUCING DRUG-INDUCED LIVER INJURY

NºPublicación: US2022298232A1 22/09/2022

Solicitante:

TEN PEAKS LLC [US]

US_2021009675_A1

Resumen de: US2022298232A1

The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.

traducir

Diagnostic methods

NºPublicación: AU2022224759A1 22/09/2022

Solicitante:

UNIV GRIFFITH [AU]

CA_3021399_A1

Resumen de: AU2022224759A1

In one aspect the invention relates to the use of single nucleotide polymorphisms (SNPs) in transient receptor potential (TRP) ion channel, acetylcholine receptor (AchR) and/or adrenergic receptor (ADR) genes as probes, tools or reagents for identi fying, screening, diagnosing, monitoring or managing/treating subjects with, or predisposed to, medical conditions (or symptoms thereof), such as chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), Gulf war syndrome (GWS), irritable bowel synNKI drome (IBS), multiple chemical sensitivity (MCS), fibromyalgia, and migraine, as well as some medical conditions caused by dys-regulation in calcium, acetylcholine, TRP and ADR, and dysregulation in the gastrointestinal, cardiovascular, neurological, genitour inary and immune systems. In another aspect the invention relates to methods, kits and assays for identifying, screening, diagnosing, monitoring or managing/treating subjects with one or more of those medical conditions or symptoms.

traducir

METHODS AND PRODUCTS FOR TREATMENT OF GASTROINTESTINAL DISORDERS

NºPublicación: JP2022541278A 22/09/2022

Solicitante:

フィンチセラピューティクスホールディングスエルエルシー

US_2022257670_A1

Resumen de: WO2021016083A1

Described herein are compositions and methods for the delivery of microbial therapeutics useful for the treatment of disorders related to intestinal dysbiosis. Described herein are compositions and methods for protecting the Gl microbiome of a subject. In various embodiments, provided herein is a pharmaceutical composition comprising an isolated or purified bacterial isolate and/or a cocktail of isolated or purified bacterial isolates (e.g. from a human, e.g. from stool of a healthy human).

traducir

ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF

NºPublicación: US2022298235A1 22/09/2022

Solicitante:

AKESO BIOPHARMA INC [CN]

BR_112022001632_PA

Resumen de: US2022298235A1

Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.

traducir

METHODS FOR PREDICTING TREATMENT RESPONSE IN ULCERATIVE COLITIS

NºPublicación: WO2022190036A2 15/09/2022

Solicitante:

JANSSEN BIOTECH INC [US]

US_2022291238_PA

Resumen de: WO2022190036A2

Biomarkers that can be used for the detection or diagnosis of disease states, preferably inflammatory bowel disease states, the identification of a treatment regimen for inflammatory bowel disease, and/or to indicate the responsiveness to the treatment regimen for inflammatory bowel disease in a subject are described. Also described are probes capable of detecting the biomarkers and related methods and kits for determining inflammatory bowel disease states and/or identification of treatment regimens for the inflammatory bowel disease states.

traducir

DETECTION OF BIOMARKERS USEFUL IN DIAGNOSING CHRONIC ENTEROPATHIES IN CATS

NºPublicación: WO2022192916A1 15/09/2022

Solicitante:

VETICA LABS INC [US]

Resumen de: WO2022192916A1

The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to diagnose and distinguish chronic enteropathies, e.g. gastrointestinal neoplasms, e.g., gastrointestinal lymphoma, and, inflammatory conditions, e.g. inflammatory bowel disease, in felines.

traducir

Methods for Predicting Treatment Response in Ulcerative Colitis

NºPublicación: US2022291238A1 15/09/2022

Solicitante:

JANSSEN BIOTECH INC [US]

WO_2022190036_PA

Resumen de: US2022291238A1

Biomarkers that can be used for the detection or diagnosis of disease states, preferably inflammatory bowel disease states, the identification of a treatment regimen for inflammatory bowel disease, and/or to indicate the responsiveness to the treatment regimen for inflammatory bowel disease in a subject are described. Also described are probes capable of detecting the biomarkers and related methods and kits for determining inflammatory bowel disease states and/or identification of treatment regimens for the inflammatory bowel disease states.

traducir

MUCIN ISOFORMS IN DISEASES CHARACTERIZED BY BARRIER DYSFUNCTION

NºPublicación: US2022291233A1 15/09/2022

Solicitante:

UNIV ANTWERPEN [BE]

CN_114502189_PA

Resumen de: US2022291233A1

The present invention relates to the field of mucin isoforms, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections, . . . In a specific embodiment, said mucin isoform is selected from the list comprising: MUC1 isoforms and MUC13 isoforms.

traducir

PREDICTING EXTRAINTESTINAL MANIFESTATIONS OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2022290241A1 15/09/2022

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

WO_2021108694_A1

Resumen de: US2022290241A1

Provided are methods, systems, and kits for identifying a patient who has or has a likelihood of developing an extra-intestinal manifestation of inflammatory bowel disease.

traducir

METHODS OF TREATING INFLAMMATORY BOWEL DISEASE (IBD) WITH ANTI- TNF-BLOCKADE

NºPublicación: WO2022192419A2 15/09/2022

Solicitante:

MASSACHUSETTS INST TECHNOLOGY [US]
SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST [US]
CHILDRENS MEDICAL CT CORP [US]

Resumen de: WO2022192419A2

The subject matter disclosed herein is generally directed to stratifying and treating inflammatory diseases. In particular, the present invention provides for detecting treatment naive cell states that predict the response of a subject having inflammatory bowel disease to anti-TNF-blockade.

traducir

DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2022290235A1 15/09/2022

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2022290235A1

This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.

traducir

System and method for diagnosing small bowel cleanliness

NºPublicación: GB2604706A 14/09/2022

Solicitante:

INTROMEDIC CO LTD [KR]

CN_114080644_PA

Resumen de: GB2604706A

The present invention relates to a system for diagnosing small bowel cleanliness. The system may comprise: a similarity analysis unit for analyzing to select a representative image of similar small bowel images from among a plurality of small bowel images; an image classification unit for, when a series of a plurality of small bowel images in which cleanliness is to be diagnosed are received in a state where the plurality of small bowel images have been learned, classifying small bowel cleanliness according to scores by predicting the small bowel cleanliness by applying the representative image to a result of the learning; and a cleanliness diagnosis unit for calculating final small bowel cleanliness for the series of the plurality of small bowel images on the basis of a score for small bowel cleanliness of the representative image and the number of small bowel images similar to the representative image.

traducir

METHODS OF SELECTING SUB-POPULATIONS OF CROHN'S DISEASE PATIENTS AMENABLE TO IL23 ANTAGONIST THERAPY

NºPublicación: WO2022187657A1 09/09/2022

Solicitante:

ASTRAZENECA COLLABORATION VENTURES LLC [US]
UNIV CALIFORNIA [US]

Resumen de: WO2022187657A1

The disclosure provides pharmacometric methods based on models incorporating pharmacokinetic and pharmacodynamic data to identify those inflammatory bowel disease patients, such as Crohn's disease patients, responsive to Interleukin 23 antagonist therapy by measuring the Interleukin 22 and/or C-reactive Protein biomarker levels in patient samples. Also provided are prognostic methods for refining the identification of such patients by distinguishing therapy-driven effects from placebo effects based on Crohn's Disease Activity Index changes resulting from IL23 antagonist therapy.

traducir

SYSTEMS AND METHODS FOR GROWTH OF INTESTINAL CELLS IN MICROFLUIDIC DEVICES

NºPublicación: US2022282221A1 08/09/2022

Solicitante:

EMULATE INC [US]
CEDARS SINAI MEDICAL CENTER [US]

AU_2020289787_A1

Resumen de: US2022282221A1

Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.

traducir

BLADDER OR BOWEL DYSFUNCTION ASSESSMENT SYSTEMS AND METHODS

NºPublicación: US2022280089A1 08/09/2022

Solicitante:

UNIV MINNESOTA [US]

Resumen de: US2022280089A1

Systems and methods for the clinical diagnosis of functional bladder states and disorders based upon contractile frequencies and variability. Systems and methods are also provided for the clinical diagnosis of functional bowel states and disorders based upon contractile frequencies and variability.

traducir

TREATING FIBROSIS AND INFLAMMATION BY INHIBITING TL1A

NºPublicación: JP2022132362A 08/09/2022

Solicitante:

セダーズ-シナイメディカルセンター

KR_20210157418_PA

Resumen de: WO2014160883A1

The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.

traducir

THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: EP4051379A1 07/09/2022

Solicitante:

UNIV CALIFORNIA [US]

CA_3155361_PA

Resumen de: WO2021086999A1

Provided herein are compositions and methods to that target microbial proteases to ameliorate the intestinal barrier dysfunction and restore mucosal integrity. They are useful to treat and prevent diseases and disorders caused by pathogenic bacteria in the gastrointestinal system of a subject.

traducir

METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2

NºPublicación: US2022273665A1 01/09/2022

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2022273665A1

Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis in a subject, with an antagonist of RIPK2 activity or expression. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with the antagonist to RIPK2 activity or expression, as described herein.

traducir

INFLAMMATORY BOWEL DISEASE DIAGNOSIS METHOD, DIAGNOSIS PROBE AND DIAGNOSIS KIT

NºPublicación: US2022276243A1 01/09/2022

Solicitante:

UNIV TOHOKU [JP]

CN_114270191_PA

Resumen de: US2022276243A1

Provided are a novel determination method, diagnostic probe, and diagnostic kit for inflammatory bowel disease. A method for determining inflammatory bowel disease includes measuring an anti-endothelial cell protein C receptor antibody (anti-EPCR antibody) in a sample collected from a subject.

traducir

METHOD OF USING GENETIC MARKERS, SINGLE NUCLEOTIDE POLYMORPHISMS AND/OR INDELS TO DETERMINE RESPONSIVENESS TO IL-10 OR IL-10 DERIVATIVE TREATMENT

NºPublicación: IL294596A 01/09/2022

Solicitante:

DEKA BIOSCIENCES INC [US]
JOHN MUMM

AU_2021205408_A1

Resumen de: US2021214782A1

The application relates to the discovery of novel gene expression profiles and/or single nucleotide polymorphisms (SNP) and/or insertions or deletions of bases (INDEL) profiles that correlate with a subject's positive receptiveness to Interleukin 10 (IL-10) or IL-10 based agent treatments. The application also relates to methods of treating patients with an IL-10 or IL-10 based agent treatment by screening, examining, or determine patients possessing a gene expression profile and/or SNP and/or INDEL profile most receptive to the treatment.

traducir

Screening and culture method

NºPublicación: NZ743000A 26/08/2022

Solicitante:

OTAKARO PATHWAYS LTD

US_2019144911_A1

Resumen de: NZ743000A

Provided are methods of culturing and staining a biomarker which may be associated with autoimmune diseases, in particular inflammatory bowel diseases like Crohn’s disease. The biomarker may be spheroplastic Mycobacterium avium subspecies paratuberculosis. The method involves culturing the biomarker in a culture media selective for mycobacteria comprising culture broth, OADC, PANTA, mycobactin J and tryptophan.

traducir

Patient Populations Amenable to IL23-Antagonist Therapy

Nº publicación: US2022267431A1 25/08/2022

Solicitante:

ASTRAZENECA COLLABORATION VENTURES LLC [DE]

JP_2022527278_A

Resumen de: US2022267431A1

The disclosure provides methods for selecting patient sub-populations, or subjects, with inflammatory conditions such as inflammatory bowel diseases that are amenable to treatment with anti-Interleukin-23 therapy by measuring the serum levels of Interleukin-22 Binding Protein and/or the serum levels of Interferon-γ. In addition, the methods are useful in identifying sub-populations of patients with inflammatory disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis that are amenable to treatment with an anti-IL-23 therapy and/or an anti-IFN-γ therapy.

traducir

Página1 de 5 nextPage por página

punteroimgVolver